Program
DM5167
A development code.
Its studies are mostly in Breast Neoplasms, led by DIGMBIO.
Furthest: phase 1, since Jul 21, 20251 company-led study, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| DIGMBIO | 11 open or running | phase 1since Jul 21, 2025 | Jul 21, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 21, 2025First study: phase 1 study in Advanced Breast CancerFirst studyNCT07101601 · 58 planned · South Korea
TargetBeta
PARP1 →read by rule
“DM5167 is a second-generation of PARP inhibitor that selectively targets the PARP-1 enzyme.”study text, by rule · the study
Other programs on PARP1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| olaparibrule | AstraZeneca | phase 4 | 78 |
| niraparibrule | GlaxoSmithKline | phase 4 | 43 |
| saruparibrule | AstraZeneca | phase 3 | 14 |
| senaparibrule | impact-therapeutics-inc | phase 2 | 12 |
| nesuparibrule | Jeil Pharmaceutical | phase 2 | 4 |
| palacaparib | AstraZeneca | phase 2 | 3 |
| PARP1 Inhibitor HS-10502rule | Hansoh Pharmaceutical Group | phase 1 | 2 |
| HSK46256rule | Haisco Pharmaceutical Group | phase 1 | 1 |
| TQB3122 | Sino Biopharmaceutical | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07101601Advanced Breast Cancer · South Korea | 1 | Recruiting | Oct 30, 2026 | 58 |
How it is read
Names in the registry
- “DM5167”, 1 entry
Codes read as this program: DM5167.
Conditions, from the studies’ own filings
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.